Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load

NCT00977054 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

59

Enrollment

OTHER

Sponsor class

Stopped Novel HCV DAA approved by FDA

Conditions

Hepatitis C

Interventions

DRUG: DFPP + Peg-IFN + RBV
DRUG: Peg-IFN + RBV

Sponsor

National Taiwan University Hospital

Collaborators

[object Object]
[object Object]